FluoGuide A/S

Stockholm Stock Exchange FLUO.ST

FluoGuide A/S Price to Book Ratio (P/B) on January 14, 2025

FluoGuide A/S Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

FluoGuide A/S 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
FluoGuide A/S 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
FluoGuide A/S average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: FLUO.ST

FluoGuide A/S

CEO	Mr. Morten Albrechtsen B.B.A., BBA, M.D.
IPO Date	June 17, 2019
Location	Denmark
Headquarters	Ole MaalOees Vej 3
Employees	7
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.

Key trends

Past 5 years